Carcinoid tumor regression with high-dose octreotide acetate: a patient report.
A patient who had carcinoid tumor of the ileum and liver and intraabdominal lymph-node metastases sustained a substantial (more than 50%) reduction of metastatic tumor burden when treated with accelerated-dosage octreotide.
Lokich
J
J
The Cancer Center of Boston, Massachussetts 02120, USA.
D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage*; D002276:Carcinoid Tumor / Q000188:drug therapy* / Q000556:secondary; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007078:Ileal Neoplasms / Q000188:drug therapy; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary; D008207:Lymphatic Metastasis; D008297:Male; D015282:Octreotide / Q000008:administration & dosage*; D012074:Remission Induction; D014057:Tomography, X-Ray Computed
D018931:Antineoplastic Agents, Hormonal; D015282:Octreotide